Works matching IS 15391604 AND DT 2020 AND VI 19 AND IP 4

Results: 13

Response to: Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. Pharm Stat. 18(2):239‐47, 2019, DOI: 10.1002/pst.1920.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 494, doi. 10.1002/pst.2008

By:

Jin, Kun;
Dunn, Billy

Publication type:

Article

Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. Pharm Stat. 18 (2):239‐47, 2019, DOI: 10.1002/pst.1920.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 492, doi. 10.1002/pst.2007

By:

Edland, Steven D.;
Raghavan, Nandini;
Ard, M. Colin

Publication type:

Article

Restricted mean survival time as a summary measure of time‐to‐event outcome.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 436, doi. 10.1002/pst.2004

By:

Hasegawa, Takahiro;
Misawa, Saori;
Nakagawa, Shintaro;
Tanaka, Shinichi;
Tanase, Takanori;
Ugai, Hiroyuki;
Wakana, Akira;
Yodo, Yasuhide;
Tsuchiya, Satoru;
Suganami, Hideki

Publication type:

Article

START: single‐to‐double arm transition design for phase II clinical trials.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 454, doi. 10.1002/pst.2005

By:

Shi, Haolun;
Zhang, Teng;
Yin, Guosheng

Publication type:

Article

On evaluating how well a biomarker can predict treatment response with survival data.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 410, doi. 10.1002/pst.2002

By:

Mboup, Bassirou;
Blanche, Paul;
Latouche, Aurélien

Publication type:

Article

A novel quantification of information for longitudinal data analyzed by mixed‐effects modeling.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 388, doi. 10.1002/pst.1996

By:

Yuan, Min;
Li, Yi;
Yang, Yaning;
Xu, Jinfeng;
Tao, Fangbiao;
Zhao, Liang;
Zhou, Honghui;
Pinheiro, Jose;
Xu, Xu Steven

Publication type:

Article

Estimation of group means using Bayesian generalized linear mixed models.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 482, doi. 10.1002/pst.2006

By:

LaLonde, Amy;
Qu, Yongming

Publication type:

Article

Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 424, doi. 10.1002/pst.2003

By:

Ding, Xue;
Wu, Jianrong

Publication type:

Article

A resampling‐based test for two crossing survival curves.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 399, doi. 10.1002/pst.2000

By:

Liu, Tiantian;
Ditzhaus, Marc;
Xu, Jin

Publication type:

Article

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 370, doi. 10.1002/pst.1986

By:

Keene, Oliver N.;
Ruberg, Stephen;
Schacht, Alexander;
Akacha, Mouna;
Lawrance, Rachael;
Berglind, Anna;
Wright, David

Publication type:

Article

Applications of Bayesian analysis to proof‐of‐concept trial planning and decision making.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 468, doi. 10.1002/pst.1985

By:

Quan, Hui;
Chen, Xun;
Lan, Yu;
Luo, Xiaodong;
Kubiak, Rene;
Bonnet, Nicolas;
Paux, Gautier

Publication type:

Article

Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect.

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 358, doi. 10.1002/pst.1976

By:

Chu, Chenghao;
Liu, Shufang;
Rong, Alan

Publication type:

Article

Issue Information.

Published in:: Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 355, doi. 10.1002/pst.1960
Publication type:: Article